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Penicillin treatment for patients with
Community-Acquired Pneumonia in
Denmark: a retrospective cohort study
Gertrud Baunbæk Egelund1,7*, Andreas Vestergaard Jensen1,7, Stine Bang Andersen1,7, Pelle Trier Petersen1,7,
Bjarne Ørskov Lindhardt2,7, Christian von Plessen3,4, Gernot Rohde5,6 and Pernille Ravn1,7
Abstract
Background: Community-acquired pneumonia (CAP) is a severe infection, with high mortality. Antibiotic strategies
for CAP differ across Europe.
The objective of the study was to describe the epidemiology of CAP in Denmark and evaluate the prognosis of
patients empirically treated with penicillin-G/V monotherapy.
Methods: Retrospective cohort study including hospitalized patients with x-ray confirmed CAP. We calculated
the population-based incidence, reviewed types of empiric antibiotics and duration of antibiotic treatment.
We evaluated the association between mortality and treatment with empiric penicillin-G/V using logistic
regression analysis.
Results: We included 1320 patients. The incidence of hospitalized CAP was 3.1/1000 inhabitants. Median age was
71 years (IQR; 58–81) and in-hospital mortality was 8%. Median duration of antibiotic treatment was 10 days (IQR;
8–12). In total 45% were treated with penicillin-G/V as empiric monotherapy and they did not have a higher
mortality compared to patients treated with broader-spectrum antibiotics (OR 0.92, CI 95% 0.55–1.53).
Conclusion: The duration of treatment exceeded recommendations in European guidelines. Empiric monotherapy
with penicillin-G/V was commonly used and not associated with increased mortality in patients with mild to
moderate pneumonia. Our results are in agreement with current conservative antibiotic strategy as outlined in the
Danish guidelines.
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Background
Community-Acquired Pneumonia (CAP) is the most
frequent lethal infection in Europe, and a substantial
economic problem, mainly due to frequent hospital
admission [1–3]. Reported incidence ranges from 1.1 to
8:1000 in different studies [4–6]. Lower respiratory
tract infections (LRTI), including CAP, are the most
frequent indications for prescribing antibiotics [7]. Due
to the difficulties of obtaining a microbiological diag-
nosis, empirical treatment is far more common than
pathogen specific treatment [1]. In Denmark, as in
other Scandinavian countries and the Netherlands [5, 6],
empirical treatment with penicillin-G/V alone is recom-
mended for patients with a CURB-65 score < 3 and
combination therapy for patients with CURB-65 ≥ 3
(http://www.infmed.dk/guidelines). Meanwhile, European
and American guidelines recommend combination ther-
apy for all hospitalized patients [7, 8]. To which extent
monotherapy with penicillin G/V is used and whether this
approach is associated with a poorer prognosis is sparsely
documented. Moreover, there is a need to investigate the
duration of treatment because of the risk of microbiological
resistance, side-effects and higher costs that are associated
with long treatment duration. Current European guidelines
recommend 5–7 days in a responding patient [7], while
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Danish guidelines recommend 7 days antibiotic treatment
for patients with CURB-65 < 3 and 10–14 days for patients
with CURB-65 ≥ 3 (http://www.infmed.dk/guidelines).
Thus, in this study, we describe the epidemiology and
characteristics of patients hospitalized with CAP in
Denmark. Moreover, we investigate the duration of anti-
biotic treatment and the association between use of
penicillin G/V and prognosis.
Methods
Design, setting and population
We conducted a retrospective cohort study including all
patients admitted with CAP to one large regional and two
smaller local hospitals in North Zealand, Denmark. The
study period was January 1st 2011 until June 30th 2012.
The number of cases hospitalized during the study period
determined the sample size. The three hospitals supply
acute care for 360,000 inhabitants in the region with
urban and rural areas and a socio-demographically varied
population. Denmark has universal health insurance that
covers all acute care including hospital admissions.
Patients admitted with pneumonia were identified by
ICD-10 codes registered at discharge. All patients who
had one of the following ICD-10 codes either as primary
or secondary diagnosis were considered for inclusion:
pneumonia J10.0, J11.0, J12.X – J18.x and J69.X, myco-
plasma B96.0, klebsiella B96.1, ornithosis A70.X and
legionellosis A481.
We reviewed all patient files to assess whether inclu-
sion and exclusion criteria were met. Each patient could
only be included once in the study.
The inclusion criteria were: Adult patient’s ≥ 18 years
admitted to hospital with CAP. CAP was defined as a
new infiltrate on the chest X-ray assessed by the radiolo-
gist on-call and at least one of the following symptoms
of LRTI: cough, purulent expectoration, fever (≥38.3 °C
rectally or ≥37.8 °C auricular) or pathological lung aus-
cultation. Only in-patients were included in the study.
The exclusion criteria were: hospital admission during the
last 28 days, active tuberculosis or immunosuppression.
Patients were classified as immunosuppressed if they
had received treatment with corticosteroids (≥ 20 mg
prednisolone-equivalent/day > 14 days), were HIV-positive,
had received cancer-chemotherapy during the last 28 days
and had neutropenia (neutrophil granulocytes < 1000/μl) or
were immunosuppressed after an organ transplantation.
Patients admitted from nursing home and patients
with frequent healthcare contacts were considered as
having acquired pneumonia in the community [9, 10]
and were not excluded from the cohort.
Data collection and variables
We registered data into the CAPNETZ database
(www.capnetz.de) and into a local database in EpiData
entry 3.1 (www.epidata.com). Data collection was per-
formed from September 2014 until January 2015. All
data stem from electronic patient files as well as labora-
tory, microbiological and radiological databases.
For each patient, we recorded demographics, comor-
bidities, symptoms, clinical values including CURB-65
[11], and biochemical test results on admission. Pa-
tients were divided in to risk groups according to
CURB-65 score (score 0–1, 2 or 3–5). The number of
co-morbidities was assessed by categorizing patients
into three groups based on the sum of conditions
(none, one, and more than one). In addition, we re-
corded microbiological test results, complications and
the length of the hospital admission (LOS). We regis-
tered the total duration of antibiotic treatment (LOAB)
and duration of intravenous antibiotic treatment (LOI-
VAB). Only the therapeutic agents given initially were
recorded. We followed patients for 6 months after
admission, to register deaths. Variables not mentioned
in the patient file were noted as missing, except for co-
morbidities which were recorded as absent if not
mentioned.
Outcome measures, exposures and confounders
The main outcomes were in-hospital (short term) and
90-day (long term) mortality. Both outcomes were reg-
istered from electronic patient files, which also contain
information on deaths outside of hospital. Patients were
grouped according to empirical antibiotic treatment,
which was the main exposure evaluated in this study.
Patients who received empirical treatment with mo-
notherapy penicillin-G/V were compared with patients
receiving empirical treatment with all other antibiotics,
as monotherapy or in combination. CURB-65 score,
number of co-morbidities (0, 1 or >1), admission to the
ICU, and age were viewed as potential confounders.
Confounding by indication could influence the results,
which was addressed by adjusting for confounders, espe-
cially CURB-65 score. Further, we stratified patients by
CURB-65 score and compared the two treatment groups
within risk groups.
Statistics
We report descriptive statistics at baseline as counts
(%) and as mean with standard deviation (SD) or me-
dians with 25th to 75th interquartile range (IQR). When
patients died in hospital, we recorded LOS as missing.
For patients who died while on antibiotic treatment, we
recorded LOIVAB and LOAB as missing values. Group
comparisons between the two treatment groups and
subgroup analysis were performed with chi-square test
for categorical variables and Wilcoxon rank-sum test
for continuous variables, which did not adhere to the
normal distribution. The association between treatment
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with empiric penicillin-G/V monotherapy and mortality
was evaluated with logistic regression analysis and ad-
justed for potential confounders (CURB65, number of
comorbidities, admission to the ICU and age). Missing
data are accounted for in Table 1 and only patients with
complete data on outcome and potential confounders
were included in the adjusted analysis.
All p-values were two-sided and a p-value of <0.05
was regarded statistically significant.
We calculated the incidence of CAP only for 2011 by
dividing the number of new cases by the number of
persons at risk (inhabitants 18 years or older).
We used SAS for Windows statistical software, version
7.1 (SAS Institute, Inc., Carey, NC).
Results
Overall 3504 patients were hospitalized and diagnosed
with pneumonia during the 18 months study-period
(Fig. 1). The majority of patients were excluded because
they did not have an infiltrate on the chest x-ray or they
had a nosocomial infection. Ultimately 1320 patients
were included in this study and constitute the CAP-
North cohort.
The incidence of hospitalized CAP, calculated on the
basis of the population in the region, was 3.1:1000,
increasing with age to 8.9:1000 in patients > 65 years and
14.7:1000 in patients >75 years (Fig. 2).
Baseline characteristics
Patient characteristics on admission are shown in Table 1.
The median age was 71 years (IQR; 58–81), 11% were
nursing-home residents and 60% had one or more co-
morbidities. One or more chronic respiratory conditions
were present in 363 (28%) patients. The majority of
patients (53%) presented with mild (CURB-65: 0–1) and
moderate (29%) (CURB-65: 2) CAP, and 31% had multi-
lobular infiltrates on chest x –ray.
Microbiological findings
Overall, 19% (248/1320) of the patients and 23%
(248/1083) of those who had a sample taken, had a
pathogen detected. Streptococcus pneumoniae (n = 67)
was the most common followed by Haemophilus in-
fluenza (n = 57), and Mycoplasma pneumoniae (n = 36)
(Table 2).
Blood cultures were performed in 74% of the patients
and microscopy and culture of sputum samples in 38.5%
(Table 3). 66 patients had bacteraemia. In patients diag-
nosed with Streptococcus pneumonia 60% (40/67) suf-
fered from bacteraemia, while this only applied for 5%
(3/57) of patients diagnosed with Haemophilus Influen-
zae. Microbiological testing was not performed in 237
(18%) patients.
Table 1 Patient characteristics on admission
Patient characteristics Study population
N = 1320
Age, median (IQR) 71 (58–81)
Gender, male 47% (626)
Nursing home, Yes 11% (145)
Co-morbidities
COPD 19% (243)
Asthma 8% (105)
Other chronic respiratory diseasea 4% (49)
Malignancy 9% (119)
Chronic heart disease 24% (320)
Chronic liver disease 1% (12)
Chronic kidney failure 3% (41)
Chronic neurological disease 14% (188)
Diabetes 12% (162)
Number of comorbidities
One 35% (466)
More than one 25% (325)
Biochemistry, median (IQR)
CRP, mg/l 108 (47–214)
White blood cell count, x 109/l 12.2 (9.2–15.7)
Urea, mmol/l 6 (4–9)
Vital parameters on admission, median (IQR)
Diastolic blood pressure, mmHg 75 (65–85)
Systolic blood pressure, mmHg 133 (119–149)
Pulse rate,/min 94 (81–106)
Respiratory rate,/min 20 (16–24)
Temperature, °C 37.7 (37.0–38.5)
Oxygen therapy 58% (744)
Findings on chest x-ray
Multilobar infiltrate 31% (403)
Risk assessment
CURB-65: 0–1 53% (605)
CURB-65: 2 29% (330)
CURB-65: 3–5 18% (202)
Antibiotic treatmentb
Penicillin-G/V monotherapyc 45% (590)
Penicillin-G/V in combinationd 6% (74)
Macrolide monotherapy 3% (36)
Other beta-lactam monotherapye 30% (396)
Other beta-lactam in combinationd 10% (132)
Other 7% (92)
Data are presented as % (counts), unless otherwise indicated
COPD Chronic obstructive pulmonary disease, CRP C-reactive protein
abronchiectasis, pulmonary fibrosis, sarcoidosis, sleep apnoea and pulmonary
cancer. All variables had less than 5% missing except smoking status (294
(22%)) and respiratory rate (144 (11%))
bEmpiric therapy
cRecommended dose: 2 mio units x 3 daily adjusted according to weight and
renal function
dPreferably macrolide or quinolone
ePreferable Cefuroxime. Recommended dose: 1500 mg x 3 daily adjusted to
weight and renal function
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Empiric antibiotic treatment and clinical outcome
Penicillin-G/V was the most frequently used antibiotic,
mainly as mono-therapy (44.7%) or in combination
(5.6%), and 63 (4.8%) received the treatment orally.
Cephalosporin’s were used as monotherapy in 25.5% of
patients. In total, 77% of the patients initially received
monotherapy (Table 1).
The median LOAB was 10 days (IQR 8–12) and 70%
of the patients were treated for more than 8 days. The
median LOIVAB was 3 days (IQR 2–6). Patients were
admitted to the hospital for a median of 5 days (IQR
3–8) (Table 4).
Complications, severe outcome, and mortality were
assessed and we found that 270 (21%) had one or more
complications, 127 (9.6%) patients were admitted to the
ICU, and 111 (8%) died within the hospital. Mortality on
days 30, 90 and 180 was 11, 15 and 19% respectively
(Table 4).
Empiric treatment with small-spectrum penicillin
Patients treated with penicillin-G/V monotherapy had a
lower CURB-65 score, less co-morbidities, fewer admis-
sions to the ICU and a lower mortality in the unadjusted
analysis (Table 5). We found no association between
penicillin-G/V monotherapy and mortality after adjust-
ing for confounders: CURB-65 score, number of co-
morbidities (0, 1 or >1), admission to the ICU, and age
(Table 6).
A subgroup analysis of the patients treated with
penicillin-G/V monotherapy showed that patients who
died in-hospital compared with survivors were older, 81
(IQR; 77–89) versus 70 (IQR; 56–80) years of age
(p < 0.0001) and more often nursing home residents,
32% versus 6% (p < 0.0001). Further, they had more
comorbidities, 76% versus 53% had ≥ 1 comorbidity
(p = 0.002) and a higher CURB-65 score, 90% versus
38% had CURB-65 ≥ 2 (p < 0.0001). We found simi-
lar results when looking at 90-days mortality (data
Fig. 2 The incidence of community-acquired pneumonia
Fig. 1 Screening of patients for inclusion
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not shown). Of the 38 patients who received monotherapy
with penicillin G/V and died in-hospital, 71% had an
unknown aetiology. Of the remaining 11 patients, 3 were
infected with Streptococcus spp. susceptible to penicillin
G/V, 3 with Klebsiella pneumonia, 3 with Escherichia coli,
1 with Haemophilus influenza, and 1 with Moraxella cat-
arrhalis. Of the 8 patients with pathogens non-susceptible
to penicillin, 3 had a CURB65 score of more than 2 and
monotherapy with penicillin was therefore an incorrect
choice of empiric antibiotic according to guidelines. One
had an unknown CURB-65 score due to missing data.
We addressed whether in-hospital mortality in the differ-
ent CURB-65 categories was related to choice of empiric
treatment and we found that the in-hospital mortality for
patients treated with penicillin-G/V monotherapy with a
CURB-65 score ≤ 2 was 4.3% and not different from 5.9%
for patients treated with other than penicillin-G/V mono-
therapy (p = 0.26). Sixty-one patients received empiric treat-
ment with monotherapy penicillin-G/V despite of having a
CURB-65 score ≥ 3, and the mortality was 19.7% compared
to 19.9% for patients treated with other than penicillin-G/V
monotherapy (p = 0.98).
Discussion
The incidence of hospitalized CAP was 3.1:1000 adult
inhabitants in the Danish region of North Zealand. The
incidence increased substantially with age. Nearly half of
the patients were treated empirically with penicillin-G/V
and the median duration of antibiotic treatment was
10 days. Patients treated with penicillin-G/V had less
Table 2 Aetiology by full study population, by all microbiological tested and of pathogen specific testing
Study population Microbiologically tested Pathogen specific tests
N = 1320 N = 1083
Pathogen
Streptococcus pneumoniae 67 (5.1%) 67 (6.2%) 67/1079 (6%)a
Haemophilus Influenzae 57 (4.3%) 57 (5.3%) 57/1075 (5%)b
Mycoplasma pneumoniae 36 (2.7%) 36 (3.3%) 36/213 (17%)c
Moraxella catarrhalis 21 (1.6%) 21 (2.0%) 21/1075 (2%)b
Staphylococcus aureus 12 (0.9%) 12 (1.1%) 12/1075 (1%)b
Pseudomonas aeruginosa 11 (0.8%) 11 (1.0%) 11/1075 (1%)b
Escherichia coli 11 (0.8%) 11 (1.0%) 11/1075 (1%)b
Legionella pneumophilia 5 (0.4%) 5 (0.5%) 5/288 (1.7%)d
Others 28 (2.1%) 33 (3.0%) 33/1083 (3%)
Data are presented as counts (%)
aPathogen detected by microscopy, culture of sputum or blood or urinary test for Streptococcus pneumoniae
bPathogen detected by microscopy, culture of sputum or blood
cPathogen detected by PCR analysis
dPathogen detected by PCR analysis or urinary antigen test for Legionella pneumophilia
Table 3 Microbiological findings in different sample types
Tested n(%) Positive n (%a) Three most common
pathogens, n (%b)N = 1320
Blood, (microscopy/culture) 981 (74%) 66 (7%) Streptococcus pneumoniae, 40 (61%)
Staphylococcus areus, 4 (6%)
Escheria coli, 4 (6%)
Sputum/tracheobronchial secretion,
(microscopy/culture)
501 (38%) 149 (30%) Haemophilus influenza, 56 (36%)
Streptococcus pneumonia, 27 (18%)
Moraxella catarrhalis, 21 (14%)
Test for atypical bacteria, (PCR analysis) 213 (16%) 41 (19%) Mycoplasma pneumoniae, 35 (85%)
Legionella pneumophilia, 3 (7%)
Chlamydia pneumoniae, 2 (5%)
Urine antigen test 133 (10%) 7 (3%) Streptococcus pneumoniae, 4 (57%)
Legionella pneumophilia, 3 (43%)
aPercentage of tested
bPercentage of positive tests
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severe pneumonia than patients treated with broad-
spectrum antibiotics or combination therapy and peni-
cillin monotherapy was not associated with increased
mortality after adjusting for CURB-65, co-morbidities,
admission the ICU and age.
The incidence is comparable to other studies from the
UK, USA and Germany reporting incidences of hospital-
ized CAP of 1.1, 2.5 and 3.0 per 1000 respectively [12–14].
Microbiological sampling was not systematically per-
formed; 18% did not have any microbiological samples
taken and a pathogen was detected in only 19% of all
the patients. This low yield does not differ from most
other studies. Even in prospective studies systematically
collecting samples, the diagnostic yield is low. In a
recent study only 38% of the patient had a confirmed
microbiological diagnosis [13]. In contrast to most other
studies however, the empiric therapy was much more
restrictive; monotherapy was administered to 77% of
the patients and 45% received penicillin-G/V alone.
Penicillin-G/V monotherapy is rarely used in southern
European countries and the USA [15]. In a European
observational multicentre study, 50% of adults hospital-
ized with CAP received monotherapy but none received
penicillin-G/V [16]. Meanwhile, empiric treatment with β-
lactam as monotherapy was given to 63% of the patients
in a Dutch study [6].
The ERS guidelines for treatment of hospitalized CAP
do not recommend penicillin as monotherapy [7] whereas,
Danish guidelines during the current study recommended
benzylpencillin as monotherapy for patients with a CURB-
65/CRB-65 score < 3, and combination therapy with quin-
olones or macrolides for CURB-65 ≥ 3 (http://www.inf-
med.dk/guidelines). This is in line with guidelines
Table 4 The course of community-acquired pneumonia
Outcome Study population
N = 1320
Treatment duration, median days (IQR)
IV antibiotica 3 (2–6)
Total antibioticb 10 (8–12)
Length of stay 5 (3–8)
Complications
Any complication 21% (277)
Co-infection 14% (182)
Pneumonia associatedc 6% (79)
Renal failure 1% (15)
Stroke 1% (12)
Acute myocardial infarction 3% (34)
ICU admission 9.6% (127)
Mortality
In-Hospital 8% (111)
30 days 11% (149)
90 days 15% (203)
180 days 19% (246)
Data are presented as % (counts), unless otherwise indicated
ICU Intensive care unit, IV Intravenous
All variables have less than 5% missing
aRange: 0–95 days
bRange: 0–97 days
cempyema, including pleural effusion treated as empyema, and lung-abscess
Table 5 Comparison of patients by antibiotic treatment: penicillin-G/V monotherapy versus broad-spectrum antibiotics
Monotherapy penicillin-G/V Other than penicillin-G/V monotherapy p-value
n = 590 n = 725
Age, median (IQR) 70.5 (57–81) 72 (59–82) 0.30b
CURB-65
0–1 58.8% (295/502) 48.6% (306/630) <0.0001a
2 29.1% (146/502) 29.1% (183/630)
3–5 12.1% (61/502) 22.3% (141/630)
Co-morbidities
0 45.1% (264/585) 35.1% (252/718) 0.001a
1 32.8% (192/585) 37.7% (271/718)
> 1 22.1% (129/585) 27.2% (194/718)
ICU admission 6.1% (36/590) 12.6% (91/725) <0.0001a
In-hospital mortality rate 6.4% (38/590) 10.1% (73/725) 0.02a
90 day mortality rate 11.7% (69/590) 18.5% (134/720) <0.0009a
Data are presented as % (counts), unless otherwise indicated
aChi-square
bWilcoxon rank sum
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from other Scandinavian countries and the Netherlands
[5, 6]. The differences in recommendations are due to a
low penicillin resistance of Streptococcus pneumonia in
Denmark of < 1% whereas it is, e.g., in Spain > 10% (http://
ecdc.europa.eu/en/healthtopics/antimicrobial_resistance/
database/Pages/map_reports) and a very conservative anti-
biotic policy encouraging small spectrum antibiotic.
In our study, patients treated with penicillin-G/V had
less severe CAP. There were no differences in mortality
associated with the use of penicillin-G/V or broader-
spectrum antibiotics in the adjusted analysis, similarly to
the findings in a Danish study from 2001 [17]. Because
penicillin monotherapy was given to patients with mild
disease (CURB-65 < 3), mortality is expected to be low
independently of the treatment and we cannot conclude
whether mortality would have been lower if broad
spectrum antibiotic or combination therapy were given.
Mortality in those with CURB-65 ≤ 2 was still substantial
in both treatment groups (4.3–5.9% respectively) indicat-
ing that mortality is not solely related to initial severity
assessment, but also to comorbidities and complications
during admission [18, 19].
Patients who were treated with empiric penicillin-
G/V monotherapy and died, were older, had more co-
morbidities and a higher CURB-65 score than survivors.
Penicillin-G/V monotherapy may have been insufficient in
these patients and apparently guidelines were not followed
in some cases. Pathogens non-susceptible to penicillin
were found in 4 patients who were treated with penicillin-
G/V monotherapy, had a CURB-65 score less than 3 and
died. Although guidelines were followed for these patients,
they received empirical treatment not matching their
causative pathogen. However, due to the retrospective
design, we cannot conclude if the poor outcome was due
to monotherapy with penicillin and if outcome would
have been better with another antibiotic agent.
Overall, penicillin-G/V appears safe in the correct
patient group, namely those hospitalized with mild
to moderate CAP (CURB-65 < 3) in a setting with a
low degree of resistance of Streptococcus pneumonia
against penicillin.
In our study, the median duration of treatment with
antibiotics was 10 days and 70% of patients received
more than the maximum 8 days which is recommended
by European guidelines for responding patients [7].
Similarly, Reissig et al [20] and the REACH study [16]
reported 11 and 10 days respectively. Duration of 10–11
days, however, exceeds recommendations in European
and Danish guidelines ([7], http://www.infmed.dk/guide-
lines). Danish guidelines recommend duration of 10–14
days only for patients with CURB-65 ≥ 3, which can
explain extended treatment duration for a smaller frac-
tion of the study population. Due to the retrospective
nature, the unsystematic microbiological sampling, and
the low proportion of positive microbiological findings,
we cannot draw firm conclusion on significant risk
factors for prolonged treatment duration.
Recent studies have shown that antibiotic treatment
for 3–5 days for mild to moderate CAP does not impair
effectiveness or safety [21–23]. There is a need to focus
on assessing alternative strategies to reduce antibiotic
use in order to minimize the risk of adverse events and
antibiotic resistance associated with extended duration
of antibiotic therapy.
Comparing patients in the CAP-North cohort with
other European CAP cohorts [14, 16, 24, 25] some
differences were apparent. Compared with patients from
the CAPNETZ cohort [25], our patients were older
(mean age 72 versus 66), more frequently women (60%
versus 47%), presented with more severe CAP (18%
CURB-65 > 2 versus 4% CRB-65 > 2), and had a higher
30 days mortality (11% versus 4.3%). The differences
could be due to our inclusion exclusively of hospital-
ized patients, as well as inclusion of all patients with
severe CAP who are often challenging to include in a
prospective study.
The major strength of this study is that we were able
to identify all patients hospitalized and diagnosed with
pneumonia in our region, due to our complete regional
dataset. Our design did however not allow us to account
for patients with CAP who were given an inaccurate
ICD-10 code. We ensured that only patients with CAP
Table 6 Risk of death in patients treated with penicillin-G/V monotherapy
Univariate Multivariatea
OR (CI) P-value OR (CI) P-value
In hospital mortality
Penicillin-G/V monotherapy 0.62 (0.41–0.93) 0.02 0.92 (0.55–1.53) 0.74
broad-spectrum (ref) 1 - 1 -
90 day mortality
Penicillin-G/V monotherapy 0.58 (0.43–0.80) 0.0008 0.77 (0.52–1.14) 0.19
broad spectrum (ref) 1 - 1 -
aAdjusted for CURB-65, number of co-morbidities (0, 1 or >1), admission to an intensive care unit (Y/N) and age
OR (CI) odds ratio with 95% confidence interval. Cases used in the adjusted analysis: 1122
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were included by reviewing every patient-file for symp-
toms on admission, hospitalization within the last 28 days,
and chest-x-ray for infiltrates. Moreover, the three hospi-
tals cover both urban and rural areas of the capital region
in Denmark and thus we believe our cohort to be repre-
sentative of patients hospitalized with CAP in developed
countries. Thus, our cohort represents a “real-life” popula-
tion of patients hospitalized with CAP.
The main limitation of this study is the retrospective
design, which made us dependent on the data recorded
in the patient files and the results should be interpreted
accordingly.
The cohort consists of a heterogeneous population,
specifically patients who received treatment with mono-
therapy penicillin G/V were less sick, than patient who
received broader spectrum antibiotics, according to the
CURB65-score. We adjusted for this in the regression
analysis, but we cannot exclude that residual confound-
ing exists.
We were not able to account for changes in antibiotic
therapy after initial assessment, i.e. due to complications
or microbiological findings. Further, we could not ac-
count for the exact dosages prescribed but only rec-
ommended dosages. Furthermore, treatment duration
varied among patients.
Approximately 50% of patients had a CURB-65 score
of 0–1. It is suggested that CAP patients with a CURB-
65 score of 0–1 can be treated as outpatients, albeit
CURB-65 has several limitations and should not be the
sole basis for deciding treatment allocation [26–28].
Conclusion
The incidence of patients hospitalized with CAP was
3.1:1000. Nearly half of the patients were treated with
empiric penicillin-G/V monotherapy without an increase
in mortality. Treatment duration exceeded recent guide-
lines. Our results are in agreement with the current con-
servative antibiotic strategy outlined in Danish guidelines,
recommending penicillin treatment.
It is important to ensure compliance with guidelines
concerning treatment duration and validation of strategies
to reduce duration of treatment in order to minimize un-
necessary side-effects. Finally prospective, randomized
control trials would be necessary to confirm whether em-
piric monotherapy with penicillin-G/V is recommendable.
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